Actinogen Medical Ltd - Asset Resilience Ratio

Latest as of December 2024: 74.78%

Actinogen Medical Ltd (ACW) has an Asset Resilience Ratio of 74.78% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Actinogen Medical Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

AU$19.02 Million
≈ $13.45 Million USD Cash + Short-term Investments

Total Assets

AU$25.43 Million
≈ $17.99 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Actinogen Medical Ltd's Asset Resilience Ratio has changed over time. See Actinogen Medical Ltd shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Actinogen Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Actinogen Medical Ltd worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$19.02 Million 74.78%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$19.02 Million 74.78%

Asset Resilience Insights

  • Very High Liquidity: Actinogen Medical Ltd maintains exceptional liquid asset reserves at 74.78% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Actinogen Medical Ltd Industry Peers by Asset Resilience Ratio

Compare Actinogen Medical Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Ascendis Pharma AS
F:A71
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 1.39%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shanghai Shen Lian Biomedical Corp
SHG:688098
Biotechnology 3.87%

Annual Asset Resilience Ratio for Actinogen Medical Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Actinogen Medical Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-06-30 33.86% AU$7.22 Million
≈ $5.11 Million
AU$21.31 Million
≈ $15.08 Million
-13.35pp
2023-06-30 47.21% AU$7.18 Million
≈ $5.08 Million
AU$15.21 Million
≈ $10.76 Million
-4.71pp
2022-06-30 51.92% AU$12.10 Million
≈ $8.56 Million
AU$23.31 Million
≈ $16.49 Million
+13.28pp
2021-06-30 38.63% AU$7.10 Million
≈ $5.02 Million
AU$18.38 Million
≈ $13.00 Million
+8.77pp
2020-06-30 29.87% AU$3.56 Million
≈ $2.52 Million
AU$11.94 Million
≈ $8.45 Million
-17.21pp
2019-06-30 47.08% AU$7.64 Million
≈ $5.40 Million
AU$16.22 Million
≈ $11.48 Million
-7.83pp
2018-06-30 54.90% AU$9.90 Million
≈ $7.00 Million
AU$18.03 Million
≈ $12.75 Million
+15.83pp
2017-06-30 39.07% AU$3.99 Million
≈ $2.82 Million
AU$10.21 Million
≈ $7.22 Million
+7.98pp
2016-06-30 31.09% AU$4.03 Million
≈ $2.85 Million
AU$12.95 Million
≈ $9.16 Million
--
pp = percentage points

About Actinogen Medical Ltd

AU:ACW Australia Biotechnology
Market Cap
$105.70 Million
AU$149.39 Million AUD
Market Cap Rank
#18982 Global
#616 in Australia
Share Price
AU$0.05
Change (1 day)
+2.17%
52-Week Range
AU$0.02 - AU$0.07
All Time High
AU$0.18
About

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other ne… Read more